Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alamar BiosciencesALMR +1.24%8 Days Payable is 67.70 as of Dec. 2025, which is 34% below its 10-year median of 102.14. GuruFocus rates ALMR with a GF Score™ of 8/100. The stock has 1 warning sign investors should review. Among 795 Medical Devices & Instruments companies, Alamar Biosciences ranks worse than 50.44% on this metric.
The historical data trend for Alamar Biosciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alamar Biosciences Days Payable Chart
Alamar Biosciences Annual Data
Trend
Dec24
Dec25
Days Payable
136.57
67.70
Alamar Biosciences Semi-Annual Data
Dec24
Dec25
Days Payable
136.57
67.70
ALMR vs UFPT, BFLY, ENOV: Days Payable Comparison
For the Medical Devices subindustry, Alamar Biosciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alamar Biosciences Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Alamar Biosciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Alamar Biosciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Alamar Biosciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alamar Biosciences (ALMR) has a Days Payable of 67.70 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Alamar Biosciences and its competitors. This is 34% below median its historical median of 102.14. Over the past decade, Alamar Biosciences' Days Payable has ranged from 67.70 to 136.57. According to the industry distribution chart, Alamar Biosciences ranks #401 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 50.4%.
Is Alamar Biosciences' Days Payable too high?
Alamar Biosciences' current Days Payable of 67.70 is 34% below median its 10-year median of 102.14. Over the past 10 years, this metric has ranged from a low of 67.70 to a high of 136.57. The Medical Devices & Instruments industry median Days Payable is 67.87. Alamar Biosciences' value of 67.70 is 0.3% below this industry median. Based on the distribution chart, Alamar Biosciences ranks #401 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Alamar Biosciences has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Alamar Biosciences' Days Payable compare to UFPT and BFLY?
According to the Medical Devices & Instruments industry distribution chart, Alamar Biosciences ranks #401 out of 795 companies for Days Payable. This places Alamar Biosciences in the lower half of its industry. The industry median Days Payable is 67.87. Alamar Biosciences' value of 67.70 is 0.3% below this benchmark. Historically, Alamar Biosciences' own Days Payable has ranged from 67.70 to 136.57 over the past decade. While the company's 10-year median is 102.14 vs. the industry median of 67.87, Alamar Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alamar Biosciences's current Days Payable of 67.70 is 0.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Alamar Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alamar Biosciences's current Days Payable is 67.70, which is 34% below median its own 10-year median of 102.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alamar Biosciences stock overvalued right now?
Alamar Biosciences (ALMR) has a current Days Payable of 67.70. The current Days Payable is 67.70, which is 34% below median its 10-year median of 102.14 and 0.3% below the Medical Devices & Instruments industry median of 67.87. Alamar Biosciences' overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Alamar Biosciences (ALMR), the current Days Payable is 67.70 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
8GF Score
Get the complete analysis for ALMR
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALMR has been successfully added to your 
